Cargando…
TFAM is a novel mediator of immunogenic cancer cell death
Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic can...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980348/ https://www.ncbi.nlm.nih.gov/pubmed/29872558 http://dx.doi.org/10.1080/2162402X.2018.1431086 |
_version_ | 1783327870611881984 |
---|---|
author | Yang, Minghua Li, Changfeng Zhu, Shan Cao, Lizhi Kroemer, Guido Zeh, Herbert Tang, Daolin Kang, Rui |
author_facet | Yang, Minghua Li, Changfeng Zhu, Shan Cao, Lizhi Kroemer, Guido Zeh, Herbert Tang, Daolin Kang, Rui |
author_sort | Yang, Minghua |
collection | PubMed |
description | Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic cancer cell death in vitro and in vivo. The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner. Mechanistically, activation of JUN by spautin-1 leads to apoptosis by upregulation of pro-apoptotic BAD expression. Importantly, the release of TFAM, a mitochondrial DAMP, by apoptotic cells may contribute to spautin-1-induced ICD via its action on the receptor AGER. Indeed, cancer cells treated with spautin-1 in vitro were able to elicit an anticancer immune response when inoculated in vivo, in the absence of any adjuvant. This immunogenic effect of spautin-1-treated cancer cells was lost when TFAM or AGER were neutralized by specific antibodies. Altogether, our results suggest that spautin-1 may stimulate an apoptotic pathway that results in ICD, in TFAM- and AGER-dependent fashion. |
format | Online Article Text |
id | pubmed-5980348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-59803482018-06-05 TFAM is a novel mediator of immunogenic cancer cell death Yang, Minghua Li, Changfeng Zhu, Shan Cao, Lizhi Kroemer, Guido Zeh, Herbert Tang, Daolin Kang, Rui Oncoimmunology Original Research Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic cancer cell death in vitro and in vivo. The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner. Mechanistically, activation of JUN by spautin-1 leads to apoptosis by upregulation of pro-apoptotic BAD expression. Importantly, the release of TFAM, a mitochondrial DAMP, by apoptotic cells may contribute to spautin-1-induced ICD via its action on the receptor AGER. Indeed, cancer cells treated with spautin-1 in vitro were able to elicit an anticancer immune response when inoculated in vivo, in the absence of any adjuvant. This immunogenic effect of spautin-1-treated cancer cells was lost when TFAM or AGER were neutralized by specific antibodies. Altogether, our results suggest that spautin-1 may stimulate an apoptotic pathway that results in ICD, in TFAM- and AGER-dependent fashion. Taylor & Francis 2018-02-15 /pmc/articles/PMC5980348/ /pubmed/29872558 http://dx.doi.org/10.1080/2162402X.2018.1431086 Text en © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Original Research Yang, Minghua Li, Changfeng Zhu, Shan Cao, Lizhi Kroemer, Guido Zeh, Herbert Tang, Daolin Kang, Rui TFAM is a novel mediator of immunogenic cancer cell death |
title | TFAM is a novel mediator of immunogenic cancer cell death |
title_full | TFAM is a novel mediator of immunogenic cancer cell death |
title_fullStr | TFAM is a novel mediator of immunogenic cancer cell death |
title_full_unstemmed | TFAM is a novel mediator of immunogenic cancer cell death |
title_short | TFAM is a novel mediator of immunogenic cancer cell death |
title_sort | tfam is a novel mediator of immunogenic cancer cell death |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980348/ https://www.ncbi.nlm.nih.gov/pubmed/29872558 http://dx.doi.org/10.1080/2162402X.2018.1431086 |
work_keys_str_mv | AT yangminghua tfamisanovelmediatorofimmunogeniccancercelldeath AT lichangfeng tfamisanovelmediatorofimmunogeniccancercelldeath AT zhushan tfamisanovelmediatorofimmunogeniccancercelldeath AT caolizhi tfamisanovelmediatorofimmunogeniccancercelldeath AT kroemerguido tfamisanovelmediatorofimmunogeniccancercelldeath AT zehherbert tfamisanovelmediatorofimmunogeniccancercelldeath AT tangdaolin tfamisanovelmediatorofimmunogeniccancercelldeath AT kangrui tfamisanovelmediatorofimmunogeniccancercelldeath |